Fenghua Wang

7PUBLICATIONS
45CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targetsHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 11, 2026
Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild-type metastatic colorectal cancer: A nonrandomised clinical trial.

|Dec 31, 2023
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.

Feng-Hua Wang, Xiao-Tian Zhang, Lei Tang

|Jul 12, 2023
Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer.

Xingbin Hu, Zhenfeng Ma, Beibei Xu

|Nov 18, 2022
Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.

Xiao-Li Wei, Yang Zhang, Hong-Yun Zhao

|Aug 05, 2022
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study).

Feng Wang, Ming-Ming He, Jian Xiao

|Dec 20, 2021
Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer.

Dan-Yun Ruan, Yan-Xing Chen, Xiao-Li Wei

Pageof 2

Frequent Collaborators

4 joint publications

Rui-Hua Xu

2 joint publications

Feng Wang

2 joint publications

Yu-Hong Li

2 joint publications

Hui-Yan Luo